Bristol tax reporting (correction)
Executive Summary
Bristol-Myers Squibb's incoming tax reporting controls remain a "reportable condition," according to the company's auditors, PricewaterhouseCoopers. In a story on Bristol's latest earnings restatement, "The Pink Sheet" incorrectly reported that the tax controls are considered a "material weakness." Bristol has resolved both "material weaknesses" identified by PwC a year ago (1"The Pink Sheet" March 22, 2004, p. 24)...
You may also be interested in...
Bristol Re-Restates: Income Taxes, “Grants” May Be Ongoing Issues
Bristol-Myers Squibb still has work to do to resolve its income tax reporting processes, the company acknowledged in a 10-K filed with the Securities & Exchange Commission March 15
Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: